0.02
+0.005(+50.00%)
Currency In CAD
Address
570 Granville Street
Vancouver, BC V6C 3P1
Canada
Phone
604 248 8730
Website
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
January 02, 2014
| Name | Title | Pay | Year Born |
| Mr. Andrew Schutte | President, Chief Executive Officer & Director | 62,917 | 1991 |
| Mr. David Kwok CPA | Chief Financial Officer | 40,000 | N/A |
| Dr. Kevin John McElwee Ph.D. | Co-Founder & Chief Scientific Officer | 72,000 | 1970 |
| Mr. Ben Austring | Chief Legal Officer, Corporate Secretary & Chief Operating Officer | 72,000 | N/A |
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
